BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O'Bryant SE, Edwards M, Johnson L, Hall J, Villarreal AE, Britton GB, Quiceno M, Cullum CM, Graff-Radford NR. A blood screening test for Alzheimer's disease. Alzheimers Dement (Amst) 2016;3:83-90. [PMID: 27453929 DOI: 10.1016/j.dadm.2016.06.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 O'Bryant SE, Edwards M, Zhang F, Johnson LA, Hall J, Kuras Y, Scherzer CR. Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study. Alzheimers Dement (Amst) 2019;11:374-82. [PMID: 31080873 DOI: 10.1016/j.dadm.2019.03.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
2 Peña-Bautista C, Baquero M, Vento M, Cháfer-Pericás C. Omics-based Biomarkers for the Early Alzheimer Disease Diagnosis and Reliable Therapeutic Targets Development. Curr Neuropharmacol 2019;17:630-47. [PMID: 30255758 DOI: 10.2174/1570159X16666180926123722] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
3 Johnson LA, Zhang F, Large S, Hall J, O'Bryant SE. The impact of comorbid depression-diabetes on proteomic outcomes among community-dwelling Mexican Americans with mild cognitive impairment. Int Psychogeriatr 2020;32:17-23. [PMID: 31658917 DOI: 10.1017/S1041610219001625] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Baldacci F, Lista S, O'Bryant SE, Ceravolo R, Toschi N, Hampel H; Alzheimer Precision Medicine Initiative (APMI). Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. Methods Mol Biol 2018;1750:139-55. [PMID: 29512070 DOI: 10.1007/978-1-4939-7704-8_9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
5 O'Bryant SE, Zhang F, Johnson LA, Hall J, Edwards M, Grammas P, Oh E, Lyketsos CG, Rissman RA. A Precision Medicine Model for Targeted NSAID Therapy in Alzheimer's Disease. J Alzheimers Dis 2018;66:97-104. [PMID: 30198872 DOI: 10.3233/JAD-180619] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
6 Moni F, Petersen ME, Zhang F, Lao PJ, Zimmerman ME, Gu Y, Gutierrez J, Rizvi B, Laing KK, Igwe KC, Sathishkumar M, Keator D, Andrews H, Krinsky-McHale S, Head E, Lee JH, Lai F, Yassa MA, Rosas HD, Silverman W, Lott IT, Schupf N, O'Bryant S, Brickman AM. Probing the proteome to explore potential correlates of increased Alzheimer's-related cerebrovascular disease in adults with Down syndrome. Alzheimers Dement 2022. [PMID: 35212182 DOI: 10.1002/alz.12627] [Reference Citation Analysis]
7 O'Bryant SE, Zhang F, Petersen M, Hall JR, Johnson LA, Yaffe K, Braskie M, Vig R, Toga AW, Rissman RA; HABLE Study Team. Proteomic Profiles of Neurodegeneration Among Mexican Americans and Non-Hispanic Whites in the HABS-HD Study. J Alzheimers Dis 2022. [PMID: 35180110 DOI: 10.3233/JAD-210543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lee H, Ugay D, Hong S, Kim Y. Alzheimer's Disease Diagnosis Using Misfolding Proteins in Blood. Dement Neurocogn Disord 2020;19:1-18. [PMID: 32174051 DOI: 10.12779/dnd.2020.19.1.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hampel H, O'Bryant SE, Castrillo JI, Ritchie C, Rojkova K, Broich K, Benda N, Nisticò R, Frank RA, Dubois B, Escott-Price V, Lista S. PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease. J Prev Alzheimers Dis 2016;3:243-59. [PMID: 28344933 DOI: 10.14283/jpad.2016.112] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
10 O'Bryant SE, Petersen M, Zhang F, Johnson L, Mason D, Hall J. Analysis of a precision medicine approach to treating Parkinson's disease: Analysis of the DATATOP study. Parkinsonism Relat Disord 2021;94:15-21. [PMID: 34864471 DOI: 10.1016/j.parkreldis.2021.11.027] [Reference Citation Analysis]
11 Lin H, Himali JJ, Satizabal CL, Beiser AS, Levy D, Benjamin EJ, Gonzales MM, Ghosh S, Vasan RS, Seshadri S, Mcgrath ER. Identifying Blood Biomarkers for Dementia Using Machine Learning Methods in the Framingham Heart Study. Cells 2022;11:1506. [DOI: 10.3390/cells11091506] [Reference Citation Analysis]
12 O'Bryant SE, Zhang F, Petersen M, Johnson L, Hall J, Rissman RA. A Precision Medicine Approach to Treating Alzheimer's Disease Using Rosiglitazone Therapy: A Biomarker Analysis of the REFLECT Trials. J Alzheimers Dis 2021;81:557-68. [PMID: 33814447 DOI: 10.3233/JAD-201610] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Massa F, Meli R, Morbelli S, Nobili F, Pardini M. Serum neurofilament light chain rate of change in Alzheimer's disease: potentials applications and notes of caution. Ann Transl Med 2019;7:S133. [PMID: 31576340 DOI: 10.21037/atm.2019.05.81] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Dey J, Roberts A, Mahari S, Gandhi S, Tripathi PP. Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide. Front Bioeng Biotechnol 2022;10:873811. [DOI: 10.3389/fbioe.2022.873811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 Zhang F, Petersen M, Johnson L, Hall J, O'Bryant SE. Recursive Support Vector Machine Biomarker Selection for Alzheimer's Disease. J Alzheimers Dis 2021;79:1691-700. [PMID: 33492292 DOI: 10.3233/JAD-201254] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, Kiddle SJ, Batrla R, Blennow K. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol 2018;14:639-52. [PMID: 30297701 DOI: 10.1038/s41582-018-0079-7] [Cited by in Crossref: 194] [Cited by in F6Publishing: 186] [Article Influence: 64.7] [Reference Citation Analysis]
17 Deiner S, Baxter MG, Mincer JS, Sano M, Hall J, Mohammed I, O'Bryant S, Zetterberg H, Blennow K, Eckenhoff R. Human plasma biomarker responses to inhalational general anaesthesia without surgery. Br J Anaesth 2020;125:282-90. [PMID: 32536445 DOI: 10.1016/j.bja.2020.04.085] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
18 Kim M, Legido-quigley C. Small molecule biomarkers in Alzheimer’s disease. OCL 2018;25:D404. [DOI: 10.1051/ocl/2018027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
19 Roubroeks JAY, Smith AR, Smith RG, Pishva E, Ibrahim Z, Sattlecker M, Hannon EJ, Kłoszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Wahlund LO, Aarsland D, Proitsi P, Hodges A, Lovestone S, Newhouse SJ, Dobson RJB, Mill J, van den Hove DLA, Lunnon K. An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. Neurobiol Aging 2020;95:26-45. [PMID: 32745807 DOI: 10.1016/j.neurobiolaging.2020.06.023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
20 Zhang F, Petersen M, Johnson L, Hall J, O'Bryant SE. Accelerating Hyperparameter Tuning in Machine Learning for Alzheimer's Disease With High Performance Computing. Front Artif Intell 2021;4:798962. [PMID: 34957393 DOI: 10.3389/frai.2021.798962] [Reference Citation Analysis]
21 Gupta VB, Hone E, Pedrini S, Doecke J, O'Bryant S, James I, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Martins RN; AIBL Research Group. Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. Alzheimers Dement (Amst) 2017;8:60-72. [PMID: 28508031 DOI: 10.1016/j.dadm.2017.04.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
22 Petrella C, Di Certo MG, Barbato C, Gabanella F, Ralli M, Greco A, Possenti R, Severini C. Neuropeptides in Alzheimer’s Disease: An Update. CAR 2019;16:544-58. [DOI: 10.2174/1567205016666190503152555] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
23 Petersen M, Zhang F, Krinsky-McHale SJ, Silverman W, Lee JH, Pang D, Hall J, Schupf N, O'Bryant SE. Proteomic profiles of prevalent mild cognitive impairment and Alzheimer's disease among adults with Down syndrome. Alzheimers Dement (Amst) 2020;12:e12023. [PMID: 32435687 DOI: 10.1002/dad2.12023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR Jr, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry 2018;19:244-328. [PMID: 29076399 DOI: 10.1080/15622975.2017.1375556] [Cited by in Crossref: 151] [Cited by in F6Publishing: 131] [Article Influence: 30.2] [Reference Citation Analysis]
25 Zeng N, Li H, Peng Y. A new deep belief network-based multi-task learning for diagnosis of Alzheimer’s disease. Neural Comput & Applic. [DOI: 10.1007/s00521-021-06149-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
26 O'Bryant SE, Mielke MM, Rissman RA, Lista S, Vanderstichele H, Zetterberg H, Lewczuk P, Posner H, Hall J, Johnson L, Fong YL, Luthman J, Jeromin A, Batrla-Utermann R, Villarreal A, Britton G, Snyder PJ, Henriksen K, Grammas P, Gupta V, Martins R, Hampel H; Biofluid Based Biomarker Professional Interest Area. Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement 2017;13:45-58. [PMID: 27870940 DOI: 10.1016/j.jalz.2016.09.014] [Cited by in Crossref: 138] [Cited by in F6Publishing: 132] [Article Influence: 23.0] [Reference Citation Analysis]
27 Phan TX, Malkani RG. Sleep and circadian rhythm disruption and stress intersect in Alzheimer's disease. Neurobiol Stress 2019;10:100133. [PMID: 30937343 DOI: 10.1016/j.ynstr.2018.10.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
28 O'Bryant SE, Petersen M, Hall J, Johnson LA; HABS-HD Study Team. Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice. Alzheimers Dement 2022. [PMID: 35235702 DOI: 10.1002/alz.12647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Schipke CG, Günter O, Weinert C, Scotton P, Sigle J, Kallarackal J, Kabelitz D, Finzen A, Feuerhelm-heidl A. Definition and quantification of six immune- and neuroregulatory serum proteins in healthy and demented elderly. Neurodegenerative Disease Management 2019;9:193-203. [DOI: 10.2217/nmt-2019-0003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
30 Royall DR, Palmer RF; Alzheimer’s Disease Neuroimaging Initiative. A δ Homolog for Dementia Case Finding with Replication in the Alzheimer's Disease Neuroimaging Initiative. J Alzheimers Dis 2019;67:67-79. [PMID: 30507569 DOI: 10.3233/JAD-171053] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
31 Petersen ME, Rafii MS, Zhang F, Hall J, Julovich D, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W, Lott I, Klunk W, Head E, Christian B, Foroud T, Lai F, Diana Rosas H, Zaman S, Wang MC, Tycko B, Lee JH, Handen B, Hartley S, Fortea J, O'Bryant S; Alzheimer’s Biomarker Consortium –Down Syndrome (ABC-DS). Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. J Alzheimers Dis 2021;79:671-81. [PMID: 33337378 DOI: 10.3233/JAD-201167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
32 O'Bryant SE, Zhang F, Petersen M, Hall JR, Johnson LA, Yaffe K, Mason D, Braskie M, Barber RA, Rissman RA, Mapstone M, Mielke MM, Toga AW; HABLE Study Team. A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among community-dwelling Mexican Americans and non-Hispanic Whites: A method for increasing representation of diverse populations in clinical research. Alzheimers Dement 2021. [PMID: 34057802 DOI: 10.1002/alz.12382] [Reference Citation Analysis]
33 O'Bryant SE. Introduction to special issue on Advances in blood-based biomarkers of Alzheimer's disease. Alzheimers Dement (Amst) 2016;3:110-2. [PMID: 27453933 DOI: 10.1016/j.dadm.2016.06.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
34 O'Bryant S, Petersen M, Hall J, Johnson L, Yaffe K, Braskie M, Toga AW, Rissman RA; HABLE study team. Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: Results from the HABLE study. Alzheimers Dement 2021. [PMID: 34310015 DOI: 10.1002/alz.12404] [Reference Citation Analysis]
35 Julian A, Rioux-Bilan A, Ragot S, Krolak-Salmon P, Berrut G, Dantoine T, Hommet C, Hanon O, Page G, Paccalin M. Blood Inflammatory Mediators and Cognitive Decline in Alzheimer's Disease: A Two Years Longitudinal Study. J Alzheimers Dis 2018;63:87-92. [PMID: 29614665 DOI: 10.3233/JAD-171131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Petersen ME, O'Bryant SE. Blood-based biomarkers for Down syndrome and Alzheimer's disease: A systematic review. Dev Neurobiol 2019;79:699-710. [PMID: 31389185 DOI: 10.1002/dneu.22714] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]